Acute Myeloid Leukemia

Positive Phase 2 SY-1425 Results for AML and MDS

Positive Phase 2 SY-1425 Results for AML and MDS

Nancy Simonian, MD, discusses the results at ASH 2018.

Clinical Activity in Patients With MCL-1-Dependent R/R AML

Clinical Activity in Patients With MCL-1-Dependent R/R AML

Joshua Zeidner, MD, discusses stage 1 findings at the ASH 2018 meeting.

Updated Findings on Treatment Options for Patients With AML

Updated Findings on Treatment Options for Patients With AML

Rod A. Humerickhouse, MD, PhD, discusses findings from AbbVie at the ASH 2018 meeting.

No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AML

No Survival Benefit Found With Allogeneic Hematopoietic Cell Transplantation in Older Patients With AML

By

At first glance, the data on 695 patients with advanced myeloid leukemia (AML) seem to support a survival advantage of allogeneic hematopoietic cell transplantation (HCT) compared with no transplantation.

Posttransplant AML Relapse Linked to Pathways Influencing Immune Function

Posttransplant AML Relapse Linked to Pathways Influencing Immune Function

By

There were no previously unknown AML-specific mutations or structural variations in immune-related genes among patients with AML who had undergone transplant.

Enhancing the Delivery of Checkpoint Inhibitors in Patients with AML

Enhancing the Delivery of Checkpoint Inhibitors in Patients with AML

By

In mice models, the systemic delivery of blood platelets that were coated with anti-PD-1 antibodies and conjugated to HSCs halted the recurrence of leukemia.

Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments

Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments

By

There were 11 genes identified in BeatAML — called in at least 1% of patients — that were not originally recognized in previous AML sequencing studies.

FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML

FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML

By

Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.

FDA Approves Ivosidenib for <i>IDH1</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

By

Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

By

Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

By

Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

By

The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.

AML: Somatic Mutation Clearance May Be Prognostic for Survival

AML: Somatic Mutation Clearance May Be Prognostic for Survival

By

Researchers determined 3 levels of somatic mutation clearance based on VAF of residual mutations at CR.

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

Measurable Residual Disease After Induction May Predict Outcomes in Acute Myeloid Leukemia

By

Findings from previous studies suggests that multiparameter flow cytometric minimal residual disease may be used to predict outcomes in acute myeloid leukemia.

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

By

The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.

Romiplostim May Not Increase Acute Myeloid Leukemia Risk

Romiplostim May Not Increase Acute Myeloid Leukemia Risk

By

Previous studies showed that romiplostim for thrombocytopenia in MDS improved hematologic outcomes but may increase the risk of AML.

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

Radioactive Iodine Increases Risk of AML, CML in Patients With Thyroid Cancer

By

The risk of AML decreased after 2 years, returning to baseline within 6 years of WDTC diagnosis, but the risk of CML remained elevated for up to 10 years.

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

High-dose Cytarabine Significantly Improves Disease-free Survival in Adult AML

By

Researchers randomly assigned 597 patients with newly diagnosed AML to receive intermediate- or conventional-dose cytarabine plus homoharringtonine and daunorubicin.

Long-term Effects of Midostaurin Maintenance Are Unknown in <i>FLT3</i>-mutated AML

Long-term Effects of Midostaurin Maintenance Are Unknown in FLT3-mutated AML

By

At the end of maintenance, 57% and 64% of patients remained in the midostaurin arm or the placebo arm, respectively. There were 16 relapse events after maintenance in the midostaurin arm and 7 relapses and 2 deaths in the placebo arm.

Acute Leukemia: Highlights from ASH 2017

Acute Leukemia: Highlights from ASH 2017

Elias Jabbour, MD, discusses the latest developments in the treatment of acute and chronic leukemia from the ASH 2017 meeting.

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

By

For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

FDA Grants Gilteritinib Fast Track Designation for FLT3-positive AML

By

Gilteritinib inhibits the FLT3 mutations observed in up to one-third of patients with AML, FLT3 internal tandem duplication, and the FLT3 tyrosine kinase domain.

Cabozantinib May Be Effective for Acute Myeloid Leukemia

Cabozantinib May Be Effective for Acute Myeloid Leukemia

By

Standard cytotoxic chemotherapy remains the standard treatment for AML, though a large proportion of patients relapse and/or develop resistance to conventional therapy, indicating a need for new treatments.

Novel Therapy May Overcome Chemotherapy Resistance in AML

Novel Therapy May Overcome Chemotherapy Resistance in AML

By

Researchers analyzed human AML samples to determine potential selective targets in leukemia stem cells, the source of resistance to standard chemotherapy.

Composite Complete Response Improved Guadecitabine Acute Myeloid Leukemia

Composite Complete Response Improved Guadecitabine Acute Myeloid Leukemia

By

Guadecitabine, a next-generation hypomethylating agent, has been shown to have a longer half-life and to prolong periods of exposure more than its predecessors.

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

Enasidenib: Well-tolerated and May Provide Benefit in R/R AML

By

Among patients with R/R disease, 19.3% achieved complete remission (CR) and had a median overall survival of 19.7 months.

FDA Approves Daunorubicin-Cytarabine Combination for AML Subtypes

FDA Approves Daunorubicin-Cytarabine Combination for AML Subtypes

By

Approval was based on data from a randomized phase 3 trial in which researchers compared the efficacy of the daunorubicin-cytarabine combination with that of a standard regimen.

FDA Approves Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia

By

The US Food and Drug Administration approved enasidenib for the treatment of adult patients with relapsed or refractory AML with an IDH2 mutation.

Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia

Gilteritinib Granted Orphan Drug Status for Acute Myeloid Leukemia

By

The US Food and Drug Administration granted orphan drug designation to gilteritinib for the treatment of AML.

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

By

Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs